The International Generic and Biosimilar Medicines Association (IGBA) entered into a Non-State Actor (NSA) agreement with WHO in 2022 to support countries in improving access to generic medicines and health products. Following the successful implementation of the initial agreement, a renewal for the 2025–2027 period has been approved. This collaboration aims to strengthen strategic areas that contribute to equitable access to essential medicines globally.
WHO’s engagement with IGBA is governed by the Framework of Engagement with Non-State Actors (FENSA), adopted by the World Health Assembly in 2016. FENSA was developed as part of WHO’s broader governance reform agenda to enhance coherence in global health and ensure transparency, accountability, and consistency in WHO’s interactions with external stakeholders.
The collaboration between WHO and IGBA under this framework reflects a shared commitment to improving access to affordable, quality-assured generic and biosimilar medicines, particularly in low- and middle-income countries. The upcoming meeting will serve as a platform to review progress and refine joint activities in light of evolving global health priorities and financial constraints.
